Adult Palatopharyngoplasty: Trends in Morbidity and Mortality from the NSQIP Database.


Journal

The Annals of otology, rhinology, and laryngology
ISSN: 1943-572X
Titre abrégé: Ann Otol Rhinol Laryngol
Pays: United States
ID NLM: 0407300

Informations de publication

Date de publication:
Jan 2021
Historique:
pubmed: 23 6 2020
medline: 5 1 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

Describe the postop morbidity of adults undergoing palatopharyngoplasty (PPP). Adults who underwent PPP were studied using ACS-NSQIP (American College of Surgeons National Surgical Quality Improvement Program) database (2016-2017) via CPT code 42145. Analyzed outcomes included length of stay (LOS), readmission, reoperation, and postop complications. Predictive variables were age, gender, BMI, comorbidities. A total of 1081 patients (73.7% male, mean age 42.0 years, range 18-79 years) were included. 95 (8.8%) were diabetic, 183 (16.9%) were smokers, 30 (2.8%) had preoperative dyspnea. 328 (30.3%) took medicine for hypertension. Concurrent procedures occurred in 646 (59.76%), 357 (33.02%) had nasal procedures, 320 (29.60%) had tonsil procedures, 66 (6.11%) had tongue procedures. Within 30 days postop, there were two (0.19%) mortalities. Complications included six wound infections, two dehiscences, four with pneumonia, two pulmonary embolisms, three myocardial infarctions, one DVT, three sepsis, one UTI, one who required CPR, and two who were ventilated for >48 hours. Five required reintubation. A total of 41 (3.79%) returned to OR for a related reason, at least 27 (65.90%) for bleeding. LOS ranged from 0 to 15 days, median 1 day. Overall 38 (3.52%) were readmitted for a related reason, 12 (31.58%) for bleeding and three (7.89%) for pain. Using a significance level of 0.002 (Bonferroni correction), LOS varied with presence of any concurrent procedure, BMI, and estimated probability of mortality and morbidity indices; readmission and reoperation had no significantly associated variables. PPP is associated with low frequency but significant morbidity and mortality.

Identifiants

pubmed: 32567393
doi: 10.1177/0003489420936711
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5-11

Auteurs

Christopher Gates (C)

Department of Internal Medicine, West Virginia University School of Medicine, Robert C. Byrd Health Sciences Center, Morgantown, WV, USA.

Jad Ramadan (J)

West Virginia University Rockefeller Neuroscience Institute, Morgantown, WV, USA.

Steven Coutras (S)

Department of Otolaryngology-Head and Neck Surgery, West Virginia University School of Medicine, Robert C. Byrd Health Sciences Center, Morgantown, WV, USA.

Michele Carr (M)

Department of Otolaryngology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH